Leukemia, Myeloid, Acute

Oncology
30
Pipeline Programs
18
Companies
32
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
13
9
7
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
457%
Monoclonal Antibody
229%
ADC
114%
+ 25 programs with unclassified modality

Competitive Landscape

18 companies ranked by most advanced pipeline stage

Astex Pharmaceuticals
Astex PharmaceuticalsUK - Cambridge
1 program
1
SGI-110Phase 31 trial
Active Trials
NCT02348489CompletedEst. Jun 2019
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
8 programs
4
1
3
BI 2536Phase 21 trial
BI 811283Phase 21 trial
VolasertibPhase 2Small Molecule1 trial
DecitabinePhase 1/21 trial
BI 836858Phase 11 trial
+3 more programs
Active Trials
NCT01690624Completed30Est. May 2018
NCT01662505Completed19Est. May 2015
NCT02722135Withdrawn0Est. Sep 2018
+5 more trials
argenx
argenxBelgium - Zwijnaarde
4 programs
2
1
1
AzacitidinePhase 2
ARGX-110Phase 1/2
CusatuzumabPhase 1Monoclonal Antibody
CusatuzumabPhase 1Monoclonal Antibody
Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
1 program
1
CPX-351Phase 21 trial
Active Trials
NCT03335267Completed30Est. May 2020
M&
Merck & Co.RAHWAY, NJ
1 program
1
SCH 727965Phase 21 trial
Active Trials
NCT00798213Terminated29Est. Apr 2010
Chipscreen Biosciences
Chipscreen BiosciencesChina - Shenzhen
1 program
1
Venetoclax Combining Chidamide and AzacitidinePhase 21 trial
Active Trials
NCT05603884RecruitingEst. Dec 2026
Vor Biopharma
Vor BiopharmaMA - Cambridge
3 programs
2
VCAR33Phase 1/21 trial
VOR33Phase 1/21 trial
VOR33N/A1 trial
Active Trials
NCT05309733Terminated10Est. May 2025
NCT05984199Terminated38Est. May 2025
NCT04849910Terminated67Est. May 2025
MaaT Pharma
MaaT PharmaFrance - Lyon
1 program
1
Autologous Fecal Microbiota TransplantationPhase 1/21 trial
Active Trials
NCT02928523CompletedEst. Jun 2018
ImmunityBio
ImmunityBioSAN DIEGO, CA
1 program
1
FludarabinePhase 1/2
Angel Pharmaceuticals
Angel PharmaceuticalsChina - Zhejiang
1 program
1
FludarabinePhase 1/21 trial
Active Trials
NCT01898793TerminatedEst. Apr 2022
Novartis
NovartisBASEL, Switzerland
1 program
1
HDM201Phase 1/25 trials
Active Trials
NCT03760445Withdrawn0Est. Jun 2023
NCT03940352Terminated52Est. Aug 2024
NCT03714958Completed12Est. Sep 2023
+2 more trials
Aptose Biosciences
Aptose BiosciencesCA - San Diego
1 program
1
TuspetinibPhase 1/2Small Molecule1 trial
Active Trials
NCT03850574RecruitingEst. Apr 2027
DS
Daiichi SankyoChina - Shanghai
3 programs
3
AC220Phase 12 trials
AC220Phase 11 trial
DS-3201bPhase 11 trial
Active Trials
NCT01468467Completed13Est. Mar 2015
NCT00462761Completed76Est. Dec 2009
NCT01390337Completed19Est. Feb 2015
+1 more trials
Bayer
BayerLEVERKUSEN, Germany
1 program
1
BAY1436032Phase 11 trial
Active Trials
NCT03127735Completed27Est. Mar 2019
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
CC-90009Phase 11 trial
Active Trials
NCT04336982Terminated22Est. Apr 2024
Celularity
CelularityFLORHAM PARK, NJ
1 program
1
PNK-007Phase 11 trial
Active Trials
NCT02781467TerminatedEst. Dec 2017
PTC Therapeutics
1 program
1
PTC299Phase 11 trial
Active Trials
NCT03761069Terminated33Est. Dec 2021
Pfizer
PfizerNEW YORK, NY
1 program
Gemtuzumab OzogamicinN/AADC1 trial
Active Trials
NCT04337138Completed32Est. Jul 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Astex PharmaceuticalsSGI-110
Chipscreen BiosciencesVenetoclax Combining Chidamide and Azacitidine
Jazz PharmaceuticalsCPX-351
Merck & Co.SCH 727965
Boehringer IngelheimVolasertib
Boehringer IngelheimBI 811283
Boehringer IngelheimBI 2536
Vor BiopharmaVCAR33
Vor BiopharmaVOR33
NovartisHDM201
Aptose BiosciencesTuspetinib
Boehringer IngelheimDecitabine
MaaT PharmaAutologous Fecal Microbiota Transplantation
Angel PharmaceuticalsFludarabine
AbbVieCC-90009

Showing 15 of 32 trials with date data

Clinical Trials (32)

Total enrollment: 1,099 patients across 32 trials

NCT02348489Astex PharmaceuticalsSGI-110

SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction

Start: Mar 2015Est. completion: Jun 2019
Phase 3Completed
NCT05603884Chipscreen BiosciencesVenetoclax Combining Chidamide and Azacitidine

VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Start: Dec 2022Est. completion: Dec 2026
Phase 2Recruiting
NCT03335267Jazz PharmaceuticalsCPX-351

Investigator Initiated Trial of CPX-351 for Untreated Acute Myeloid Leukemia

Start: Oct 2017Est. completion: May 202030 patients
Phase 2Completed
NCT00798213Merck & Co.SCH 727965

SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)

Start: Jan 2009Est. completion: Apr 201029 patients
Phase 2Terminated
NCT00804856Boehringer IngelheimVolasertib

Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia

Start: Nov 2008Est. completion: Apr 2021180 patients
Phase 2Completed
NCT00632749Boehringer IngelheimBI 811283

BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment

Start: May 2008Est. completion: Mar 201468 patients
Phase 2Completed
NCT00701766Boehringer IngelheimBI 2536

BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia

Start: Oct 200671 patients
Phase 2Completed
NCT05984199Vor BiopharmaVCAR33

Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant

Start: Dec 2023Est. completion: May 202538 patients
Phase 1/2Terminated
NCT04849910Vor BiopharmaVOR33

Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS

Start: Dec 2021Est. completion: May 202567 patients
Phase 1/2Terminated
NCT03760445NovartisHDM201

HDM201 Added to CT in R/R or Newly Diagnosed AML

Start: Nov 2019Est. completion: Jun 20230
Phase 1/2Withdrawn
NCT03850574Aptose BiosciencesTuspetinib

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Start: Mar 2019Est. completion: Apr 2027
Phase 1/2Recruiting
NCT02632721Boehringer IngelheimDecitabine

A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)

Start: Jun 2016Est. completion: Jan 202349 patients
Phase 1/2Completed
NCT02928523MaaT PharmaAutologous Fecal Microbiota Transplantation

PreventiOn of DYSbioSis Complications With Autologous FMT in AML Patients

Start: Jun 2016Est. completion: Jun 2018
Phase 1/2Completed
NCT01898793Angel PharmaceuticalsFludarabine

Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Start: Aug 2014Est. completion: Apr 2022
Phase 1/2Terminated
NCT04336982AbbVieCC-90009

A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia

Start: Aug 2020Est. completion: Apr 202422 patients
Phase 1Terminated
NCT03940352NovartisHDM201

HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

Start: Jun 2019Est. completion: Aug 202452 patients
Phase 1Terminated
NCT03714958NovartisHDM201

Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type

Start: Dec 2018Est. completion: Sep 202312 patients
Phase 1Completed
NCT03761069PTC TherapeuticsPTC299

Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias

Start: Oct 2018Est. completion: Dec 202133 patients
Phase 1Terminated
NCT03127735BayerBAY1436032

BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)

Start: Jun 2017Est. completion: Mar 201927 patients
Phase 1Completed
NCT03110354Daiichi SankyoDS-3201b

DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)

Start: Apr 2017Est. completion: Mar 202128 patients
Phase 1Terminated
NCT02722135Boehringer IngelheimVolasertib

A Study to Find a Safe Dose of Volasertib Given in Addition to Standard Salvage Chemotherapy in Children (Age 3 Months to Less Than 18 Years) With Acute Myeloid Leukaemia, in Whom Front-line Chemotherapy Failed

Start: Nov 2016Est. completion: Sep 20180
Phase 1Withdrawn
NCT02781467CelularityPNK-007

A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)

Start: Jul 2016Est. completion: Dec 2017
Phase 1Terminated
NCT02601378NovartisHDM201

A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.

Start: Feb 2016Est. completion: Jan 2022107 patients
Phase 1Terminated
NCT02343172NovartisHDM201

Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma

Start: Mar 2015Est. completion: Oct 201974 patients
Phase 1Completed
NCT02003573Boehringer Ingelheimdecitabine iv

Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML)

Start: Jan 2014Est. completion: May 201613 patients
Phase 1Terminated
NCT01690624Boehringer IngelheimBI 836858

BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients With AML in Complete Remission With High Risk to Relapse

Start: Sep 2012Est. completion: May 201830 patients
Phase 1Completed
NCT01662505Boehringer IngelheimVolasertib

Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML)

Start: Aug 2012Est. completion: May 201519 patients
Phase 1Completed
NCT01468467Daiichi SankyoAC220

A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)

Start: Apr 2012Est. completion: Mar 201513 patients
Phase 1Completed
NCT01390337Daiichi SankyoAC220

A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)

Start: Oct 2011Est. completion: Feb 201519 patients
Phase 1Completed
NCT00462761Daiichi SankyoAC220

A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status

Start: Jan 2007Est. completion: Dec 200976 patients
Phase 1Completed
NCT05309733Vor BiopharmaVOR33

A Long-term Follow-up Study of Patients Who Received VOR33

Start: Apr 2022Est. completion: May 202510 patients
N/ATerminated
NCT04337138PfizerGemtuzumab Ozogamicin

A Study Of Treatment Patterns And Clinical Outcomes In Patients Diagnosed With Acute Myeloid Leukemia Who Received Mylotarg in the Real-World

Start: Apr 2020Est. completion: Jul 202032 patients
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 1,099 patients
18 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)